LICENSE AGREEMENT (AP23573 in Medical Devices)License Agreement • March 16th, 2010 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”) is made effective as of October 9, 2007 (the “Effective Date”), by and between ARIAD Pharmaceuticals, Inc. and ARIAD Gene Therapeutics, Inc., both corporations with a principal place of business at 26 Landsdowne Street, Cambridge, MA 02139 (collectively, “ARIAD”), and ICON Medical Corp., a Delaware corporation with a principal place of business at 1414 South Green Road, Suite 309, Cleveland, Ohio 44121 (“ICON”). ARIAD and ICON are each hereafter referred to individually as a “Party” and together as the “Parties.”
WAIVER AND AMENDMENT NO. 5 TO CREDIT AGREEMENTCredit Agreement • March 16th, 2010 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS WAIVER AND AMENDMENT NO. 5 (this “Amendment”) dated as of December 14, 2009 to the CREDIT AGREEMENT (the “Credit Agreement”) dated March 12, 2003, as amended by the Amendment No. 1 to Credit Agreement dated December 31, 2003 and further amended by the Amendment No. 2 to Credit Agreement dated December 31, 2004, and further amended by the Amendment No. 3 to Credit Agreement dated March 26, 2008, and further amended by the Amendment No. 4 to Credit Agreement dated June 19, 2009 is by and among ARIAD Pharmaceuticals, Inc., a Delaware corporation and ARIAD Corporation, a Delaware corporation (hereinafter sometimes referred to collectively as the “Borrowers”) and RBS Citizens, National Association (the "Lender"). All capitalized terms not defined herein but defined in the Credit Agreement shall have the meanings given to such terms in the Credit Agreement.
